Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031928 · ClinicalTrials.gov registry record · Phase 1
Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors
A Phase 1 study of Brain and Central Nervous System Tumors, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 3,000
- Enrollment target
- 9
- Study locations
NCT00031928: Completed Phase 1 study of Brain and Central Nervous System Tumors, sponsored by National Cancer Institute (NCI).
NCT00031928 is a Phase 1 study of Brain and Central Nervous System Tumors that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3,000 participants, above the 117-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (2464% higher). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031928, a Phase 1 study of Brain and Central Nervous System Tumors, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3,000 participants
- Enrollment target
- 9
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to determine the effectiveness of mafosfamide in treating patients who have progressive or refractory meningeal tumors.
Conditions Studied
Interventions
- DRUG mafosfamide
Study Locations (9)
Texas
- Texas Children's Cancer Center - Houston
- University of Texas - MD Anderson Cancer Center - Houston
California
- Children's Hospital Los Angeles - Los Angeles
District of Columbia
- Children's National Medical Center - Washington D.C.
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
Minnesota
- Mayo Clinic Cancer Center - Rochester
Vermont
- Neurological Research Center, Inc. - Bennington
Washington
- Children's Hospital and Regional Medical Center - Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2002-01 |
| Phase | Phase 1 |
What the finished NCT00031928 record still lists
NCT00031928 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 117-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (2464% higher).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which mafosfamide is the first listed.
NCT00031928 lists 9 locations in 8 states (Texas, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00031928 about?
NCT00031928 is a clinical study titled "Mafosfamide in Treating Patients With Progressive or Refractory Meningeal Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to determine the effectiveness of mafosfamide in treating patients who have progressive or refractory meningeal tumors.
What is the current status of trial NCT00031928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3,000 participants. The study started on 2002-01.
What conditions does trial NCT00031928 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00031928?
The interventions under investigation include: mafosfamide (DRUG).
Who is sponsoring clinical trial NCT00031928?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00031928 being conducted?
This trial has 9 study locations across California, District of Columbia, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00031928's enrollment target sits among peer trials
3,000 1st of 45 higher than 45 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
-
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
COMPLETED · Phase 1
-
SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 1
-
Sirolimus in Treating Patients With Glioblastoma Multiforme
COMPLETED · Phase 1
-
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
COMPLETED · Phase 1
-
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia